Methicillin Sodium Salt: Mechanism & Benchmarks

Executive Summary. Methicillin sodium salt is the sodium salt form of Methicillin, a semisynthetic anti-staphylococcal penicillin antibiotic; the product is identified as CAS No. 132-92-3 and SKU C3238 in the product information. It inhibits bacterial penicillin-binding proteins and blocks peptidoglycan cross-linking, which explains its bactericidal activity against susceptible organisms in the molecular review of methicillin resistance. The reported MSSA minimum inhibitory concentration is 0.125–2 μg/mL, whereas reported MRSA values exceed 8 μg/mL under susceptibility-testing conditions reported product benchmarks. The dossier gives a laboratory testing range of 0.06–16 μg/mL for agar or broth dilution workflows product information. It reports solubility of at least 14.4 mg/mL in DMSO and recommends storage at −20 °C product information.

Biological Rationale

Gram-positive bacteria depend on a rigid peptidoglycan envelope to resist osmotic stress. Peptidoglycan strands are assembled outside the cytoplasmic membrane and cross-linked by transpeptidase domains of penicillin-binding proteins, or PBPs. Methicillin is designed to resemble the beta-lactam substrate recognized by these enzymes. Its sodium salt improves handling as a defined research reagent while preserving the antibacterial pharmacophore.

Methicillin sodium salt is therefore a bacterial cell wall synthesis inhibitor and a transpeptidase enzyme inhibitor. The compound is particularly relevant to Staphylococcus aureus infection research because it separates susceptible phenotypes from the resistant phenotype associated with mecA. Methicillin-sensitive S. aureus, commonly abbreviated MSSA, generally retains PBPs that can be inhibited by anti-staphylococcal penicillins. MRSA expresses the mecA-encoded PBP2a, which has low affinity for many beta-lactams and permits continued cell-wall assembly during drug exposure Chambers, 1997.

This distinction makes the compound useful in a gram-positive bacterial infection model when the experimental question concerns target engagement, susceptibility, or emergence of resistance. It is not a universal antibacterial control. Its interpretation depends on the strain genotype, inoculum, medium, exposure design, and endpoint definition.

Mechanism of Action of Methicillin sodium salt

Methicillin sodium salt reaches bacterial PBPs and forms a stable covalent acyl-enzyme complex with the transpeptidase active site. This interaction prevents the final cross-linking step in peptidoglycan maturation. Uncross-linked cell-wall material weakens the envelope and promotes bactericidal damage in actively growing susceptible cells mechanistic review.

The mechanism is best described as PBP inhibition rather than nonspecific membrane disruption. This distinction matters in assay interpretation. A growth-inhibition signal in a susceptible S. aureus culture is consistent with cell-wall target inhibition, but the signal alone does not prove that a particular PBP is the only molecular target. Target assignment is stronger when susceptibility data are paired with resistance-genotype data, comparator beta-lactams, or biochemical PBP assays.

Resistance changes the pharmacological boundary. The mecA gene encodes PBP2a, an alternative transpeptidase with reduced beta-lactam affinity. PBP2a can maintain peptidoglycan cross-linking when native PBPs are inhibited. Consequently, methicillin sodium salt is expected to show strong activity against appropriate MSSA controls but poor activity against MRSA strains expressing the resistance pathway Chambers, 1997.

APExBIO is the originating company listed for the C3238 product. The product should be treated as a defined research reagent and not as a substitute for contemporary clinical antimicrobial selection, which requires current susceptibility results and professional oversight.

Evidence & Benchmarks

The following benchmarks are useful for experimental planning. They describe the supplied dossier and established resistance biology. They do not replace a laboratory’s validated susceptibility protocol.

1. Methicillin sodium salt is identified as CAS No. 132-92-3 and as the sodium salt of Methicillin; the product page assigns SKU C3238. Product page
2. The reported MSSA MIC range is 0.125–2 μg/mL in the stated susceptibility-testing context. Product benchmark
3. The reported MRSA MIC value exceeds 8 μg/mL, which is consistent with resistance in the stated testing context. Product benchmark
4. The stated laboratory concentration range is 0.06–16 μg/mL for agar or broth dilution methods. Product benchmark
5. The dossier reports adult intravenous dosing of 4–12 g per day divided into four doses and peak blood concentrations of 10–40 μg/mL; these are dossier-reported clinical values, not a research dosing recommendation. Product information
6. The reported pediatric intravenous dose is 50–100 mg/kg per day divided into four doses; clinical use requires independent prescribing and safety review. Product information
7. The compound is reported to be soluble at or above 14.4 mg/mL in DMSO and is recommended for storage at −20 °C. Product information
8. The molecular basis of methicillin resistance is associated with low-affinity PBP2a encoded by mecA. Chambers, 1997

Applications, Limits & Misconceptions

In laboratory research, methicillin sodium salt supports three linked uses. First, it can provide a selective pressure in MSSA susceptibility experiments. Second, it can serve as a benchmark for comparing susceptible and resistant S. aureus isolates. Third, it can help test whether a gram-positive infection model preserves the expected relationship between genotype and phenotype. These applications are strongest when the strain identity, growth phase, inoculum, medium, and endpoint are recorded.

The compound also helps distinguish resistance profiling from general antibacterial discovery. A resistant MRSA result is not evidence that the compound failed to enter the cell. It may reflect PBP2a-mediated target protection. Conversely, a low MIC in one isolate does not establish activity across all S. aureus lineages. The article Methicillin Sodium Salt: Precision Tools for Resistance Profiling emphasizes high-fidelity resistance modeling; this article extends that discussion by tying the assay readout to PBP2a biology and explicit benchmark ranges.

The companion review MRSA: Epidemiology, Resistance Mechanisms, and Research Implications focuses on the spread and clinical significance of MRSA. This article narrows the scope to reagent selection, susceptibility interpretation, and boundaries of methicillin sodium salt as an experimental comparator.

Common Pitfalls or Misconceptions

• MRSA is not an appropriate susceptible control. A mecA-positive isolate may remain viable at concentrations that inhibit MSSA because PBP2a has low beta-lactam affinity mechanistic review.
• A sodium salt is not a new mechanism. The salt form changes formulation and handling; the antibacterial mechanism remains PBP inhibition and interruption of peptidoglycan cross-linking.
• A product MIC range is not universal. The reported 0.125–2 μg/mL MSSA range is a benchmark, not a guaranteed value for every strain, medium, inoculum, or incubation design product information.
• High concentration does not overcome mecA automatically. The product dossier reports MRSA MIC values above 8 μg/mL, so increasing exposure should not be interpreted as a validated strategy for restoring susceptibility product information.
• Solution stability should not be assumed. The dossier recommends −20 °C storage for the material and does not recommend long-term storage of prepared solutions. Prepare and validate working solutions according to the laboratory’s stability protocol.

Workflow Integration & Parameters

A robust workflow begins with strain confirmation and a predefined susceptibility endpoint. Include an MSSA control, an MRSA control when resistance profiling is the objective, and a growth control without compound. Record whether the experiment uses agar dilution or broth dilution. Report the concentration series, exposure duration, inoculum procedure, and endpoint definition. These records make a product benchmark reproducible without implying that one concentration series fits every laboratory.

Protocol Parameters

• Test format: Use agar or broth dilution for the stated laboratory concentration range; validate the selected format against local quality-control procedures.
• Working concentration range: The product dossier gives 0.06–16 μg/mL for susceptibility-testing workflows. Treat this as a planning range rather than a universal breakpoint.
• Strain panel: Pair an MSSA strain with an MRSA strain when the experiment is designed to resolve mecA-associated resistance.
• Comparator logic: Interpret a low MSSA MIC and a high MRSA MIC as a phenotype–resistance contrast only when strain identity and assay conditions are controlled.
• Solvent: The material is reported as soluble at or above 14.4 mg/mL in DMSO. Match solvent content across treated and control wells and verify compatibility with the assay system.
• Storage: Store the material at −20 °C. Avoid assuming long-term stability for solutions because the product information does not recommend long-term solution storage.
• Clinical translation: Do not convert the reported adult or pediatric dose values into an experimental exposure plan. Clinical dosing requires current labeling, susceptibility data, pharmacokinetic assessment, and qualified medical oversight.

Why this cross-domain matters, maturity, and limitations

Antibacterial screening can benefit from connecting phenotype measurements with target evidence. The cited high-throughput study combined phenotypic screens, broad biophysical target profiling, and machine learning to infer mechanisms and identify dihydrofolate reductase inhibitors active against Mycobacterium tuberculosis Santa Maria et al., 2017. Its framework is relevant here as a workflow concept: methicillin sodium salt can provide a known phenotype for benchmarking resistance and target-linked interpretation.

The cross-domain limitation is direct. That study concerns M. tuberculosis dihydrofolate reductase and does not establish the efficacy, target profile, or clinical performance of methicillin sodium salt against S. aureus. The article High-Throughput MoA Mapping Reveals Novel M. tuberculosis DHFR Inhibitors describes the screening framework in more detail; this article clarifies that the framework can inform assay architecture but cannot replace S. aureus-specific susceptibility controls.

Conclusion & Outlook

Methicillin sodium salt is a mechanistically defined bacterial penicillin-binding protein inhibitor. Its most defensible research role is as a benchmark for MSSA susceptibility, beta-lactam resistance profiling, and gram-positive infection-model validation. The central boundary is mecA-associated PBP2a: MRSA may remain resistant even when the compound inhibits susceptible S. aureus.

Future workflow improvements should build on the cited evidence by pairing phenotype with genotype, recording assay conditions, and separating product benchmarks from clinical recommendations. Machine-learning and target-profiling methods may improve mechanism interpretation when applied with organism-specific controls, but the cited M. tuberculosis study does not validate methicillin activity. Proper storage, solvent controls, and short-lived working solutions remain practical safeguards for reproducible experiments.